Literature DB >> 24777280

Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

Hannah L Rose1, Wai Khoon Ho.   

Abstract

There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called 'triple positivity' for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardiolipin (aCL) and anti-β2 glycoprotein-I (anti-β2Gp-I) antibodies are all detected). Management of these cases is extremely difficult and little is available in the medical literature to guide therapy. This report describes the use of regular plasma exchanges (PEx) to bring about a successful pregnancy outcome in a woman with secondary APS and previous recurrent miscarriages. The patient was also anticoagulated with enoxaparin and administered aspirin, prednisolone, azathioprine and hydroxychloroquine. Through regular PEx and immunomodulation therapy, levels of aCL and anti-β2Gp-I antibodies were monitored and documented to fall as pregnancy progressed. Although the outcome in this case was successful, further experience is required before this regimen can be accepted as the standard of care for these patients at very high risk of pregnancy loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777280     DOI: 10.1007/s11239-014-1080-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  14 in total

Review 1.  Guidelines on the investigation and management of antiphospholipid syndrome.

Authors:  David Keeling; Ian Mackie; Gary W Moore; Ian A Greer; Michael Greaves
Journal:  Br J Haematol       Date:  2012-02-08       Impact factor: 6.998

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

4.  Removal kinetics of therapeutic apheresis.

Authors:  Roberto Reverberi; Lorenzo Reverberi
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

Review 5.  APS--controversies in diagnosis and management, critical overview of current guidelines.

Authors:  Vittorio Pengo
Journal:  Thromb Res       Date:  2011-02       Impact factor: 3.944

6.  Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity.

Authors:  Amelia Ruffatti; Marta Tonello; Teresa Del Ross; Anna Cavazzana; Chiara Grava; Franco Noventa; Francesco Tona; Sabino Iliceto; Vittorio Pengo
Journal:  Thromb Haemost       Date:  2006-09       Impact factor: 5.249

Review 7.  Antiphospholipid syndrome.

Authors:  Guillermo Ruiz-Irastorza; Mark Crowther; Ware Branch; Munther A Khamashta
Journal:  Lancet       Date:  2010-09-06       Impact factor: 79.321

Review 8.  Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.

Authors:  Amelia Ruffatti; Piero Marson; Vittorio Pengo; Maria Favaro; Marta Tonello; Maria Bortolati; Daria Minucci; Giustina De Silvestro
Journal:  Autoimmun Rev       Date:  2006-12-01       Impact factor: 9.754

Review 9.  Managing lupus patients during pregnancy.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

Review 10.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.

Authors:  G Ruiz-Irastorza; M Ramos-Casals; P Brito-Zeron; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

View more
  1 in total

Review 1.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.